科研之友
微信
新浪微博
Facebook
分享链接
摘要
AimAcute kidney injury (AKI) is associated with increased mortality. While angiotensin-converting enzyme inhibitors (ACEI) are known to slow progression of chronic kidney disease, their role in AKI remains unclear. MethodsThe Randomised Evaluation of Normal vs. Augmented Level Replacement Therapy (RENAL) study data were analysed according to ACEI use over time. The primary outcome was all-cause mortality at 90 days following randomisation. Analyses used a multivariate Cox model adjusted for either baseline or for time-dependent covariates, and a sensitivity analysis of patients surviving to at least the median time to ACEI initiation. ResultsOf the 1463 participants with available data on ACE inhibitors usage, 142 (9.7%) received ACEI at least once during study data collection. Participants treated with ACEI were older (P=0.02) and had less sepsis at baseline (P<0.001). ACEI use was significantly associated with lower mortality at 90 days (HR 0.46, 95% CI 0.30-0.71, P<0.001), and an increase in renal replacement therapy-free days (P<0.001), intensive care unit-free days (P<0.001) and hospital free-days (P<0.001) after adjusting for baseline covariates. Using the time-dependent analysis, however, the effect of ACEI administration was not significant (HR 0.78, 95% CI 0.51-1.21, P=0.3). The sensitivity analysis in day 8 survivors produced similar results. ConclusionIn the RENAL study cohort, the use of ACEI during the study was not common and, after adjustment for time-dependent covariates, was not significantly associated with reductions in mortality. Further assessment of the effect of ACEI use in AKI patients is needed. Summary at a Glance In this RENAL study cohort, the use of ACEI in AKI during the study was not common and was not significantly associated with reductions in mortality.
- 出版日期2014-10
